- Home
- POR vs BLTE Comparison
POR vs BLTE Comparison
Compare POR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | POR | BLTE |
|---|---|---|
| Founded | 1889 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.1B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | POR | BLTE |
|---|---|---|
| Price | $48.62 | $151.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $46.27 | ★ $149.00 |
| AVG Volume (30 Days) | ★ 1.3M | 252.9K |
| Earning Date | 10-31-2025 | 11-10-2025 |
| Dividend Yield | ★ 4.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $3,511,000,000.00 | N/A |
| Revenue This Year | $5.15 | N/A |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | $17.50 | ★ N/A |
| Revenue Growth | ★ 5.09 | N/A |
| 52 Week Low | $39.55 | $49.00 |
| 52 Week High | $51.14 | $160.55 |
Technical Indicators
Market Signals| Indicator | POR | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 69.59 |
| Support Level | $49.06 | $115.41 |
| Resistance Level | $51.14 | $160.55 |
| Average True Range (ATR) | 0.73 | 12.57 |
| MACD | -0.32 | 1.79 |
| Stochastic Oscillator | 8.01 | 79.92 |
Price Performance
Historical ComparisonAbout POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation along with 100 megawatts of energy storage.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.